|

Efficacy and Safety of Zotarolimus-eluting Stent Overexpansion With OCT

RECRUITINGSponsored by Yonsei University
Actively Recruiting
SponsorYonsei University
Started2022-03-23
Est. completion2026-12-31
Eligibility
Age19 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05340361

Summary

Investigators aimed to evaluate efficacy and safety of expansion capacity of zotarolimus-eluting Stent assessed by optical coherence tomography (OCT) in vivo study.

Eligibility

Age: 19 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients, ≥19 years of age, who were diagnosed with IHD requiring stent implantation for lesion with size discrepancy between proximal and distal reference diameter over 1mm, such as tapered long lesion or bifurcation lesion, confirmed by OCT
* The decision to participate voluntarily in this study and the written consent of the patient

Exclusion Criteria:

* Patients with hypersensitivity or contraindication to antiplatelet treatment
* Female of childbearing potential, who possibly plans to become pregnant any time after enrollment into this study.
* Patients with a life expectancy shorter than 1 year

Conditions4

Coronary Artery DiseaseHeart DiseaseOptical Coherence TomographyStent

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.